EBAMed‘s CardioKit system was designed to address Ventricular Tachycardia, a potentially fatal heart condition that affects an estimated 50 million people globally. This condition is projected to increase in prevalence in the next half-century due to an aging population. EBAMed’s technology not only increases the precision of external beam delivery but also auto-adjusts radiation ablation systems for cardiac motion. This unique integration of radiation therapy and motion monitoring could provide a significant breakthrough for patients, presenting a superior alternative to drug therapy or catheter-based ablation.
Previously, EBAMed was awarded a seed loan of CHF 100,000 by the Fongit Innovation Fund (FIF) for its innovation in the medical technology sphere. The latest fundraising round is led by Panakès Partners, and includes the European Innovation Council (EIC) Fund, EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, and OCCIDENT, alongside the company’s existing investors like Mayo Clinic.
Revolutionizing the treatment of cardiac arrhythmias
EBAMed co-founder and Chairman, Giovanni Leo, expressed his enthusiasm over the successful completion of the financing round and noted that the Italian investors’ recognition was particularly gratifying. As a Swiss-Italian company, EBAMed is poised to leverage its diverse talent pool and recently opened subsidiary in Milan to expand operations in Italy.
Barbara Castellano, Partner of Panakès Partners, expressed the importance of EBAMed’s work due to the increasing global issue of cardiac arrhythmias. The limited and suboptimal therapeutic options for patients suffering from ventricular tachycardia require innovative solutions like EBAMed’s CardioKit system. Radio ablation using protons in conjunction with respiratory and cardiac gating heralds a new era of precision medicine, especially for challenging patient cases.
EBAMed CEO Marina Izzo said: “Our mission is to optimize radiotherapy for cardiac indications. With exciting developments in compensation for cardiorespiratory movements, our technology has the potential to revolutionize the treatment of cardiac arrhythmias.” She added that the fresh funding will speed up the delivery of their revolutionary technology to patients in need, potentially forming an essential component of future non-invasive ablation treatment pathways for life-threatening arrhythmias.
